InvestorsHub Logo
Followers 1
Posts 288
Boards Moderated 0
Alias Born 06/23/2013

Re: scottsmith post# 92760

Wednesday, 02/22/2017 7:44:15 PM

Wednesday, February 22, 2017 7:44:15 PM

Post# of 462570
Lots of chatter here that show why we don't need a patent. There are many paths to exclusivity, and they are provided in law as recognition that the FDA process can eat up an entire patent before approval, or much of it. Big pharma are masters of working the various exclusions for quite a while. This is not ruling out that we might get a combo approval.

One of the advantages of a potential. AVXL Biogen, that Biogen could do a combo trial with one of it's MS drugs, or maybe even one of it's ALZ candidates, and get a brand spanking new patent for the combo.
But there are plenty of paths to at least nine years exclusivity, and probably much more under existing law. There are many previous posts that detail and link to. The history and regulations.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News